Harmony Biosciences Holdings, Inc. develops and commercializes therapies for rare neurological diseases, with WAKIX® (pitolisant) as its commercial product for adult narcolepsy-associated cataplexy. News about HRMY centers on WAKIX revenue trends, market access and payer dynamics, intellectual-property protection, and product guidance.
Company updates also cover clinical and regulatory progress across its CNS pipeline, including pitolisant lifecycle programs and candidates such as EPX-100 for Dravet syndrome and Lennox-Gastaut syndrome. Recurring announcements include quarterly results, investor-conference presentations, executive and board changes, and pipeline data presentations at medical meetings.
Harmony Biosciences has completed its upsized IPO, successfully offering 6,151,162 shares of common stock at $24.00 per share, yielding gross proceeds of approximately $147.6 million. This offering included 802,325 shares sold under the underwriters' option. Shares began trading on the Nasdaq Global Market under the ticker symbol HRMY on August 19, 2020. The offering was led by Goldman Sachs, Jefferies, and Piper Sandler, with the registration statement declared effective on August 18, 2020.
Harmony Biosciences announced the pricing of its upsized initial public offering (IPO) of 5,348,837 shares at $24.00 each, aiming to raise a total of $128.4 million. The shares will start trading on the Nasdaq under the ticker symbol HRMY on August 19, 2020. An additional 802,325 shares may be purchased by underwriters within 30 days at the IPO price. This offering supports Harmony's mission of developing innovative therapies for rare neurological disorders and is expected to close on August 21, 2020, subject to customary conditions.